newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

  • INVO Fertility reported Q2 2026 revenue of $2.175 million, a 17% increase compared to $1.863 million in Q2 2025.
  • Consolidated clinic revenue rose 18% to $2.167 million, driven by organic growth & a full-quarter contribution from the acquired Family Beginnings clinic.
  • Clinic-Level Adjusted EBITDA was approximately $333,000 in Q2 2026, compared to $164,000 in Q1 2026, while the platform remained profitable before corporate expenses.
  • The company reported a net income of $0.9 million in Q2 2026, a significant turnaround from a net loss of $3.6 million in the prior-year period.
  • A $2.5 million gain on remeasurement related to the Birmingham acquisition was included in Q2 2026 earnings, whereas the prior year included $2.1 million in losses from discontinued NAYA Therapeutics operations.
  • Adjusted EBITDA for the quarter was $(1.0) million, compared to $(0.6) million in the same period last year.
  • INVO acquired remaining ownership interests in its Birmingham, Alabama clinic in June 2026, converting the operation from a joint venture to a wholly owned subsidiary.
  • Cash reserves stood at $3.7 million as of June 30, 2026, up from approximately $2.1 million at December 31, 2025.
  • The company had 2,506,969 shares of common stock outstanding as of August 14, 2026.
  • Management highlighted continued investments in operational capabilities to support expansion & a robust pipeline of U.S.-based, profitable fertility clinics for future acquisition.
  • Dr. Gretchen Collins presented five abstracts on ovarian & subendometrial platelet-rich plasma at the 2026 Midwest Reproductive Symposium International.